DO IT!

(Pitavastatin Trial)

Study Summary

Study Details

This condition of obesity with high cholesterol is sometimes called “Combined Dyslipidemia of Obesity” or CDO. When people have CDO for many years, it can cause their arteries to harden and narrow (called atherosclerosis). This can then lead to serious health problems including heart attack, stroke, or even death.

Pitavastatin is commonly known as Livalo and belongs to a group of cholesterol lowering medicines called statins. It is approved by the Food and Drug Administration (FDA) and Health Canada for use in adults and in children with another type of high cholesterol. It lowers blood total cholesterol as well as “bad” cholesterol (called LDL) that raises the risk of heart disease and heart attacks. It also increases the “good” type of cholesterol (called HDL).

For more information, visit ClinicalTrials.gov.

Check back soon for a summary of key study findings!

For more information, visit ClinicalTrials.gov.

Who was in the study?

Male or females between the age of 10 and 19 who have Combined Dyslipidemia of Obesity (CDO).

What happened during the study?

Activities in the study included:

  1. Medical History: We will review your medical chart and collect information about surgeries and medical procedures.
  2. Physical Examination: Weight and height measurements, blood pressure, head circumference and waist circumference.
  3. Blood Draw: Draw a blood sample while fasting to check lab values, take DNA samples and extra blood to be saved for future study.
  4. Pregnancy Test: for female subjects.
  5. Tanner Staging Report: Questionnaire that asks about physical maturity and development.
  6. Three Vascular Measurements: Pulse Wave Velocity, Carotid Intima-Media Thickness and Carotid Stiffness tests will be conducted to see how blood vessels function.

Each participant was in the study for 24 months.